Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
757.53-
QQQ
706.90-
BTC/USD
77257.300.9447%
DIA
520.83-
GLD
395.60-
TLT
80.75-

Allogene Therapeutics Inc

ALLONASDAQ
Trade with Public
Trade with Public
$1.76
At close: Sep 11, 5:00 PM EST
$1.78
0.021.14%
After Hours: 4:30 PM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

Allogene Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Allogene Therapeutics (ALLO).

Price Target Range — 12 Quarters

Analyst Consensus — 18 Analysts

2S.Buy
10Buy
6Hold
Consensus RatingBuy# Analysts18Avg. Consensus PT$8Upside to Avg. PT+331.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 17, 2026CitizensReni J. BenjaminMaintainedMarket Outperform$6
Apr 16, 2026JP MorganBrian ChengUpgradeUnderweight→Neutral—
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Citizens Reiterates Market Outperform on Allogene Therapeutics, Maintains $6 Price Target

Citizens analyst Reni J. Benjamin reiterates Allogene Therapeutics (NASDAQ:ALLO) with a Market Outperform and maintains $6 price target.
Benzinga Newsdesk

PRO
JP Morgan Upgrades Allogene Therapeutics to Neutral

JP Morgan analyst Brian Cheng upgrades Allogene Therapeutics (NASDAQ:ALLO) from Underweight to Neutral.
Benzinga Newsdesk

Dell To Rally More Than 21%? Here Are 10 Top Analyst Forecasts For Thursday

Analysts change outlook on top names: Mizuho downgrades PYPL, B of A increases CIEN PT, Needham raises TSM PT, HC Wainwright slashes ALLO PT, Goldman raises MS PT, Baird raises WM PT, Bernstein raises INTC PT, B of A raises PNC PT.
Avi Kapoor

PRO
HC Wainwright & Co. Maintains Buy on Allogene Therapeutics, Lowers Price Target to $11

HC Wainwright & Co. analyst Robert Burns maintains Allogene Therapeutics (NASDAQ:ALLO) with a Buy and lowers the price target from $12 to $11.
Benzinga Newsdesk

PRO
Jefferies Maintains Buy on Allogene Therapeutics, Raises Price Target to $10

Jefferies analyst Roger Song maintains Allogene Therapeutics (NASDAQ:ALLO) with a Buy and raises the price target from $6 to $10.
Benzinga Newsdesk

PRO
Bernstein Maintains Market Perform on Allogene Therapeutics, Raises Price Target to $3.85

Bernstein analyst William Pickering maintains Allogene Therapeutics (NASDAQ:ALLO) with a Market Perform and raises the price target from $1.6 to $3.85.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved